LY-83583 stimulates glucose transporter-1-mediated glucose transport independent of changes in cGMP levels

Eur J Pharmacol. 1999 Jan 29;366(1):101-9. doi: 10.1016/s0014-2999(98)00893-0.

Abstract

Exposure of Clone 9 cells, a nontransformed rat liver cell line expressing only the Glutl glucose transporter isoform, to the guanylyl cyclase inhibitor LY-83583 was found to stimulate the rate of glucose transport (approximately 7- to 8-fold in 1 h). A similar response to LY-83583 was found in NIH 3T3 fibroblasts, 3T3-L1 pre-adipocytes, and C2C12 myoblasts. Neither the rate of glucose transport in cells under control conditions nor the effect of LY-83583 on glucose transport was altered by 10, 50, or 100 microM 8-bromo-cGMP or by addition of cGMP phosphodiesterase inhibitors, zaprinast, or dipyridamole suggesting that glucose transport and the response to LY-83583 is independent of cGMP levels. In addition, the effect of LY-83583 on glucose transport was not mediated by inhibition of oxidative phosphorylation, since exposure to the agent resulted in no increase in lactate production. Incubation of Clone 9 cells in the presence of the phospholipase C inhibitor U73122, however, attenuated the glucose transport response to LY-83583. Moreover, exposure to LY-83583 resulted in a rise in cell diacylglycerol content, and preincubation with U73122 significantly diminished this rise as well as the glucose transport response to LY-83583. The stimulatory effect of LY-83583 on glucose transport was significantly blocked by thapsigargin. Down-regulation of protein kinase C activity, resulting from 24 h pre-incubation in the presence of 160 nM phorbol-12-myristate 13-acetate, did not attenuate the glucose transport response to LY-83583. It is concluded that the stimulation of glucose transport in response to LY-83583 is independent of changes in cGMP levels, is not mediated by inhibition of oxidative phosphorylation, and is mediated, at least in part, through stimulation of the phospholipase C pathway.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • 3-O-Methylglucose / pharmacokinetics
  • 3T3 Cells
  • Aminoquinolines / pharmacology*
  • Animals
  • Biological Transport / drug effects
  • Cell Line
  • Cyclic GMP / analogs & derivatives
  • Cyclic GMP / metabolism*
  • Cyclic GMP / pharmacology
  • Dose-Response Relationship, Drug
  • Enzyme Activation / drug effects
  • Enzyme Inhibitors / pharmacology*
  • Eukaryotic Cells / cytology
  • Eukaryotic Cells / drug effects
  • Eukaryotic Cells / metabolism
  • Glucose / pharmacokinetics*
  • Guanylate Cyclase / antagonists & inhibitors
  • Lactic Acid / biosynthesis
  • Mice
  • Monosaccharide Transport Proteins / physiology*
  • Type C Phospholipases / drug effects
  • Type C Phospholipases / metabolism

Substances

  • Aminoquinolines
  • Enzyme Inhibitors
  • Monosaccharide Transport Proteins
  • 3-O-Methylglucose
  • 8-bromocyclic GMP
  • Lactic Acid
  • 6-anilino-5,8-quinolinedione
  • Type C Phospholipases
  • Guanylate Cyclase
  • Cyclic GMP
  • Glucose